Sedative
PreclinicalSmall molecule
Sedative is one of 54 small molecule programs targeting Sedation. It is currently in Preclinical.
4
Indications
4
Total Trials
2
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
72 competitors in Effectiveness
#DrugCompanyPhaseTrials
1Kesimpta
NovartisPhase 3
Mounjaro
Eli LillyPhase 3
Actos
TakedaPhase 3
Nicotine Free Cigarettes
PfizerPhase 3
Botulinum Toxin a
GSKPhase 3
Gemzar
Johnson & JohnsonPhase 2
Haldol
DDePuy Orthopaedics
Phase 2
Welireg
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
Pneumococcal Conjugate Vaccine
NovartisPhase 3
Silver Diamine Fluoride
TThe University of Hong Kong
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sleep Apnea1 trial
Combination Therapy to Treat Sleep Apnea
Completed·—·N/A·NCT01633827·22 enrolled
Effectiveness1 trial
"Comparison of the Effectiveness of Conventional Radiofrequency Thermocoagulation and Chemical Ablation With Phenol on Articular Branches of Femoral and Obturator Nerves in Chronic Hip Pain"
Not yet recruiting·—·N/A·NCT06570746·48 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sedative. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details